We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Proposed Rule Would Change Names of Six Biologicals, Including Neupogen
Proposed Rule Would Change Names of Six Biologicals, Including Neupogen
September 8, 2015
Just days before Sandoz launched Zarxio, its biosimilar of Amgen’s chemotherapy drug Neupogen, the U.S. Food and Drug Administration issued a proposed rule changing both drugs’ official names, at least temporarily.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor